Filing summary
Important identity discrepancy: The request metadata names Crescent Biopharma, Inc., but the supplied filing is GlycoMimetics, Inc.’s Form 10-Q for the quarter ended March 31, 2020 (filed May 1, 2020). This summary reflects the supplied filing, not a Crescent Biopharma filing.
Business context and reporting period
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates; it has no approved products or product sales. Its lead candidate, uproleselan, is being studied in AML. The unaudited results cover the three months ended March 31, 2020, with comparison to the same quarter of 2019.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Revenue | $9.0 million | $0 |
| Research and development expense | $12.7 million | $11.8 million; up $0.9 million (8%) |
| General and administrative expense | $4.4 million | $3.4 million; up $1.1 million (32%) |
| Operating loss | $8.1 million | $15.1 million |
| Interest income | $0.45 million | $1.05 million |
| Net loss | $7.7 million | $14.1 million |
| Loss per share, basic and diluted | $0.18 | $0.33 |
| Net cash used in operating activities | $3.5 million | $14.3 million |
The $9.0 million revenue was the nonrefundable upfront payment under the Apollomics license agreement, recognized when the licensed rights were delivered. The filing does not provide a meaningful commercial gross margin; the company has no product sales. Cash and cash equivalents were $154.8 million at March 31, 2020, down from $158.2 million at December 31, 2019. Total assets were $162.1 million and total liabilities were $13.6 million. No financial borrowings are reported; liabilities include operating lease obligations, with $3.4 million in present-value lease payments. Management expected cash to fund operations into 2022, subject to assumptions and spending needs.
Material changes and developments
- R&D spending increased mainly because of greater clinical-development costs for the global Phase 3 uproleselan trial and the NCI-supported trial. Lower manufacturing and formulation costs partly offset the increase.
- G&A expense rose due to personnel costs, professional fees, and legal and patent expenses. Interest income declined amid lower average cash balances and interest rates.
- In January 2020, GlycoMimetics licensed rights to uproleselan and GMI-1687 in Greater China to Apollomics, receiving $9.0 million upfront. Potential consideration includes up to approximately $180 million in development and commercial milestones and tiered royalties; these future payments are conditional and uncertain.
- Pfizer’s rivipansel license termination became effective April 5, 2020, after its Phase 3 trial failed to meet primary and key secondary efficacy endpoints. GlycoMimetics retained the rights and was evaluating next steps; it reported no Q1 2020 revenue or payments from Pfizer.
- Common shares outstanding were 43.6 million at March 31, 2020. The company had $80 million remaining available under its at-the-market stock sales agreement; it made no sales under the facility in Q1.
Outlook, risks, and contingencies
Management expects continued operating losses and negative operating cash flows, and anticipates increased expenses as it advances clinical programs and prepares for potential future development and commercialization. The company may need additional financing; it has no committed external liquidity source other than conditional Apollomics milestone and royalty obligations. Equity or debt financing may be unavailable or dilutive, and collaboration financing could require giving up rights.
COVID-19 had slowed uproleselan Phase 3 site initiation and patient recruitment and enrollment in April 2020. The company could not determine whether the delays would be temporary or materially affect trial timing, costs, or its financial condition. Its disclosed expectation was to complete enrollment in the Phase 3 trial in the second half of 2021, but it cautioned that COVID-19 could affect timing. Other risks include trial enrollment and results, regulatory approval, manufacturing and supply continuity, commercialization, and capital access. No material legal proceedings were reported. Management stated that disclosure controls were effective as of March 31, 2020.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing identifies GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Review the Apollomics agreement’s terms, milestone conditions, royalty rates, and any later development or supply updates; only the upfront payment was recognized as Q1 revenue.
- Check subsequent disclosures on COVID-19 effects, uproleselan Phase 3 enrollment timing, and the NCI-supported trial.
- Assess the status and strategic plans for rivipansel following Pfizer’s termination and the unsuccessful Phase 3 trial.
- Reassess cash runway against actual clinical spending, financing activity, and the assumptions underlying management’s outlook into 2022.